Clinical Trial Update: Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating nitrocamptothecin for recurrent non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Nitrocamptothecin (nitrocamptothecin)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED